Glycerol phenylbutyrate

Glycerol phenylbutyrate (HPN-100; marketed as Ravicti) is a triglyceride prodrug composed of three molecules of 4-phenylbutyric acid esterified to a glycerol backbone, developed as an oral liquid nitrogen-scavenging agent for the chronic management of urea cycle disorders (UCDs) in patients whose hyperammonemia cannot be controlled by dietary protein restriction and amino acid supplementation alone. Approved by the United States Food and Drug Administration on February 1, 2013 as a new molecular entity and by the European Commission on November 27, 2015, glycerol phenylbutyrate provides an alternative pathway for waste nitrogen excretion: pancreatic lipases hydrolyze the triglyceride in the intestinal lumen to release free phenylbutyrate (PBA) and glycerol; PBA undergoes hepatic beta-oxidation to phenylacetate (PAA); PAA conjugates with glutamine via phenylacetyl-CoA:L-glutamine N-acetyltransferase in the liver and kidney to form phenylacetylglutamine (PAGN), a water-soluble metabolite containing two moles of nitrogen per mole that is excreted in urine. This conjugation pathway bypasses the deficient urea cycle enzymes and provides stoichiometric nitrogen disposal equivalent to urea on a molar basis.

The pharmacokinetic profile of glycerol phenylbutyrate is distinguished from the predecessor agent sodium phenylbutyrate (NaPBA; Buphenyl) by approximately 75 percent slower absorption of phenylbutyrate, lower peak plasma concentrations of all metabolites, and more sustained systemic exposure, resulting in more consistent ammonia control and fewer excursions above the upper limit of normal. The compound is a clear, colorless to pale yellow liquid with a density of 1.1 g/mL, is nearly odorless and nearly tasteless, contains no sodium, and delivers the phenylbutyrate-equivalent of 40 sodium phenylbutyrate tablets in approximately one teaspoon administered in the published literature. These formulation advantages address the principal compliance limitations of sodium phenylbutyrate therapy: objectionable taste and odor, high pill burden (up to 40 tablets in the published literature), and substantial sodium load (approximately 2,400 mg per maximum daily dose).

Clinical validation rests on a pivotal Phase 3 randomized double-blind crossover trial in 45 adult UCD patients demonstrating non-inferiority to sodium phenylbutyrate on 24-hour ammonia area under the curve (geometric mean ratio 0.91; 95 percent confidence interval 0.80 to 1.04), supported by pediatric studies in patients aged 2 months to 17 years showing equivalent or superior ammonia control. Long-term extension studies demonstrate maintenance of fasting ammonia within normal limits and improvement in executive function on neurocognitive testing in pediatric patients. A Phase 2 randomized double-blind placebo-controlled trial (HALT-HE) in 178 cirrhotic patients with hepatic encephalopathy demonstrated that glycerol phenylbutyrate reduced hepatic encephalopathy events (21 percent versus 36 percent on placebo; P = 0.02) and lowered ammonia levels, establishing a potential second major indication beyond urea cycle disorders.

The active metabolite phenylbutyrate is independently characterized as a histone deacetylase (HDAC) inhibitor with preclinical activity in models of glioblastoma, Parkinson's disease, and amyotrophic lateral sclerosis, adding a dimension of mechanistic interest beyond nitrogen scavenging. Safety is dominated by gastrointestinal adverse events (diarrhea, flatulence, nausea) at rates comparable to or lower than sodium phenylbutyrate, and by the theoretical risk of phenylacetate neurotoxicity at plasma PAA concentrations exceeding 500 micrograms per milliliter, a threshold not observed in clinical trials in UCD patients but requiring monitoring in hepatically impaired populations. This monograph reviews the chemistry, synthesis, and structural pharmacology of glycerol phenylbutyrate; the prodrug activation and nitrogen-scavenging mechanism; the comprehensive pharmacokinetic record across healthy adults, UCD patients, and cirrhotic patients; the clinical evidence base across urea cycle disorders and hepatic encephalopathy; sourcing, reconstitution, and handling; stack-interaction considerations; the adverse-event and safety profile; and a structured comparative assessment of five alternative nitrogen-management agents against glycerol phenylbutyrate on five competency standards.